Section Arrow
ENTA.NASDAQ
- Enanta Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/05 08:34 EST
Pre Market
Last
 13
-1.42 (-9.85%)
Bid
14
Ask
16.75
High 13 
Low 13 
Volume
Regular Hours (Closed)
Last
 14.42
-1.35 (-8.56%)
Day High 
15.93 
Prev. Close
15.77 
1-M High
17.15 
Volume 
354.28K 
Bid
14
Ask
16.75
Day Low
14.305 
Open
15.79 
1-M Low
13.75 
Market Cap 
455.31M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 15.76 
20-SMA 15.12 
50-SMA 13.15 
52-W High 17.15 
52-W Low 4.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.84/-2.56
Enterprise Value
510.06M
Balance Sheet
Book Value Per Share
2.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
65.32M
Operating Revenue Per Share
2.79
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6828 +0.0228 +3.45%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5132 +0.0028 +0.55%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.6296 +0.2796 +6.43%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.142741 +0.005841 +4.27%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.